With various trends and variables anticipated to fuel its growth in the upcoming years, the Asia Pacific Pharmaceutical Contract Development and Manufacturing Organization (CDMO) market has a bright future, recording a CAGR of 9.9% from 2023 to 2031. The market is expected to increase from US$ 60.82 billion in 2022 to US$ 140.03 billion by 2031.
Request Sample Copy of Research Report @ https://www.astuteanalytica.com/request-sample/asia-pacific-pharmaceutical-contract-development-manufacturing-organization-market
Due to factors such as increasing outsourcing of drug research and manufacturing activities by pharmaceutical companies, rising demand for complicated and specialty pharmaceuticals, and favorable government policies, the Asia Pacific pharmaceutical CDMO industry is expected to experience considerable expansion. For instance, in 2019, Chinese CDMO WuXi Biologics that it will invest $240 million to build a plant in Singapore for the production of biological medicinal substances.
Low labor costs and a booming pharmaceutical sector in the area also make it a desirable location for CDMO businesses wishing to grow their operations. Due to China’s cheap labor costs, pharmaceutical companies can reduce their manufacturing expenses by as much as 30%. Along with it, low capital and overhead costs (compared to those of the United States and Europe), tax breaks, and an undervalued currency all work together to give pharmaceutical businesses outsourcing to China a major cost advantage.
With government backing and incentives that draw international investment, emerging markets like China, India, and South Korea are likely to maintain their dominance in the Asia Pacific Pharmaceutical Contract Development and Manufacturing Organization (CDMO) market. The aging populations and rising prevalence of chronic diseases in these nations will further increase demand for CDMO services and pharmaceutical products. For instance, 179.9 million older Chinese citizens, or 81.1% of the country, had any chronic conditions. The incidence rose with advancing age and peaked between the ages of 80 and 84.
In addition to manufacturing, CDMOs are increasingly taking the lead in innovation and expanding into other spheres of the pharmaceutical industry. CDMOs can quickly increase their capabilities through acquisitions, enabling them to offer technically sophisticated services at scale. The implementation of artificial intelligence, machine learning, and automation, among other technological developments, will play a vital role in improving the effectiveness and caliber of services offered by CDMOs in the area. These developments will speed up the time it takes for pharmaceuticals to reach the market and increase overall output.
Companies Profile
Pharmaceutical companies are currently dealing with intense competition, cost pressure, technical advancements, and a surge in consolidation efforts. Despite the exponential growth in demand for biologics and generic drugs, the substantial upfront costs associated with setting up sophisticated production processes and cutting-edge technology cannot disregard. The pharmaceutical industries increasingly rely on CDMOs for clinical candidate development, manufacture, candidate registration, and market authorization to avoid these eventualities.
Pharmaceutical businesses are reviewing their laborious production procedures and looking into CDMO facilities in order to manage their assets and resources while controlling spending. For instance, in April 2023, Bridgewest introduced NovaCina, a new CDMO with an Australian base and a focus on sterile injectable medicinal items. The recently acquired facility and crew are located in Bentley, a suburb of Perth in Western Australia. Under the name NovaCinaTM, it will function as a Contract Development and Manufacturing Organisation (CDMO).
In March 2023, LGM Pharma announced that both its active pharmaceutical ingredient (API) division and its new contract development and manufacturing organization (CDMO) division had significant growth in 2022.
Full operational integration for commercial manufacturing and the two newly developed CDMO service divisions, Analytical Testing Services (ATS) and Drug Product Research & Development (R&D) completed in late 2021 after LGM purchased its CDMO business in 2020.
In January 2023, WuXi STA, a division of WuXi AppTec, declared that its first continuous manufacturing (CM) line for oral solids is operational at its pharmaceutical production facility in Wuxi City, China. A new range of oral medication development products from the contract research, development, and manufacturing organization will be offered to clients globally, enabling higher yields and quicker time to market.
To gain more insights into the market with a detailed table of content and figures, click here: https://www.astuteanalytica.com/industry-report/asia-pacific-pharmaceutical-contract-development-manufacturing-organization-market
Leading Players
- Aenova Group
- Almac Group
- Aphena Pharma Solutions
- Ardena
- Baxter Biopharma Solutions (Baxter International Inc.)
- Boehringer Ingelheim Group
- BDR Group
- Catalent Inc.
- Dalton Pharma Services
- Famar SA
- Recro Pharma, Inc. (IRISYS, LLC)
- Jubilant Life Sciences Ltd.
- Lonza Group AG
- NextPharma
- Pfizer CentreSource (Pfizer Inc.)
- Recipharm AB
- Thermo Fisher Scientific Inc. (Patheon Inc.)
- Samsung BioLogics
- Stella Lifecare
- PPD Inc.
- Other Prominent Players
Segmentation Outlook
In terms of Service Type
Over 60% of the income in the Asia Pacific Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market is likely to come from API Manufacturing. Making active pharmaceutical ingredients, or APIs gives drugs their therapeutic effects. Because of aging populations, population expansion, and an increase in the prevalence of chronic diseases, there is a rising demand for APIs.
In terms of End-User
In the global pharmaceutical Contract Development and Manufacturing Organisation (CDMO) market, big pharmaceutical companies are likely to account for more than 47% of the revenue share. This is not surprising considering the considerable resources and ability to finance investments in pharmaceutical research and development that large pharmaceutical corporations have.
Segmentation Outline
By Service Type:
- Active Pharmaceutical Ingredient (API) Manufacturing
- Small Molecule
- Large Molecule
- High Potency API (HPAPI)
- Finished Dosage Formulation (FDF) Development and Manufacturing
- Solid Dose Formulation
- Liquid Dose Formulation
- Injectable Dose Formulation
- Nutraceuticals
- Cosmeceuticals
- Drug Development Service
- Primary and Secondary Packaging Services
- Biologics Manufacturing Services
- Biologics API manufacturing services
- Biologics FDF manufacturing services
By Dosage Form-By State
- Solid
- Tablets
- Capsules
- Powder
- Semi-Solid
- Cream
- Paste
- Gel
- Liquid Dose Formulation
- Injectables
- Sterile Vials
- Single Use/Single Dose
- Multi-Use
- Ampules
- Prefilled Syringes
- Suspension
- Emulsion
- Gas Dose Formulation
- Inhaler
- Aerosols
By Route of Administration
- Oral
- Topical
- Parenteral
- Inhalations
- Others
By Indication
- Cancer
- Cardiovascular Disease
- Diabetes
- Pain
- Respiratory disease
- Other Disease
By End-User
- Big Pharmaceutical Companies
- Small & Medium-Sized Pharmaceutical Companies
- Generic Pharmaceutical Companies
- Other End Users
By Region
- China
- India
- Japan
- Australia & New Zealand
- South Korea
- ASEAN
- Rest of Asia Pacific
- Indonesia
- Malaysia
- Philippines
- Thailand
- Vietnam
- Singapore
- Rest of ASEAN
- Rest of Asia Pacific
Directly Purchase a copy of report with TOC @ https://www.astuteanalytica.com/inquire-before-purchase/asia-pacific-pharmaceutical-contract-development-manufacturing-organization-market
About Astute Analytica
Astute Analytica is a global analytics and advisory company which has built a solid reputation in a short period, thanks to the tangible outcomes we have delivered to our clients. We pride ourselves in generating unparalleled, in depth and uncannily accurate estimates and projections for our very demanding clients spread across different verticals. We have a long list of satisfied and repeat clients from a wide spectrum including technology, healthcare, chemicals, semiconductors, FMCG, and many more. These happy customers come to us from all across the Globe. They are able to make well calibrated decisions and leverage highly lucrative opportunities while surmounting the fierce challenges all because we analyze for them the complex business environment, segment wise existing and emerging possibilities, technology formations, growth estimates, and even the strategic choices available. In short, a complete package. All this is possible because we have a highly qualified, competent, and experienced team of professionals comprising of business analysts, economists, consultants, and technology experts. In our list of priorities, you-our patron-come at the top. You can be sure of best cost-effective, value-added package from us, should you decide to engage with us.
Contact us:
Aamir Beg
BSI Business Park, H-15,Sector-63, Noida- 201301- India
Phone: +1-888 429 6757 (US Toll Free); +91-0120- 4483891 (Rest of the World)
Email: sales@astuteanalytica.com
Website: www.astuteanalytica.com